CeriBell, Inc. - Common Stock (CBLL)

CeriBell (NASDAQ:CBLL) reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company’s strongest quarter of net new hospital additions since becoming public. On the company’s earnings call, Co-founder

CeriBell (CBLL) Q1 2026 Earnings Transcript

CeriBell (CBLL) Q4 2025 Earnings Call Transcript

CeriBell (CBLL) Q3 2025 Earnings Call Transcript

According to the company, its current U.S. inventory is expected to cover demand through the third quarter of 2025.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

The stock has shown solid performance despite market volatility, making it likely that insiders will sell to cash in on gains.

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.

The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and Camp4 Therapeutics each made their public debut.